share_log

亚虹医药：2023年收入大幅增长 核心产品APL-1702?新药上市申请预计Q2获受理

Yahong Pharmaceutical: Significant revenue growth in 2023 Core product APL-1702? New drug marketing applications are expected to be accepted in Q2

Gelonghui Finance ·  Apr 17 09:47

Gelonghui, April 17 | Yahong Pharmaceutical released its annual report. In 2023, the company achieved operating income of 13.7533 million yuan, an increase of 137.272 million yuan over the same period last year. The revenue growth was mainly due to sales revenue and license fee revenue generated by prazopanib tablets and neratinib maleate tablets in Q4 of 2023. In addition, the company's core products have made many advances. For example, APL-1702 is actively preparing to submit a new drug marketing application, and it is expected that Q2 will be accepted; APL-1706's new drug marketing application has been accepted; and the phase II clinical trial analysis of APL-1202 combined with PD-1 has achieved positive results.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment